Are you looking for a way to make your projects go more smoothly? Do you want to have data assembled into easy to read charts and graphs? Agile Project Management Software will allow you to do that at a reasonable cost. It will allow management to be able to look at a single chart to see where each team member is on the project designated.
You will want to look for someone who specializes in project management systems. You will want glowing recommendations from other clients who have used their services. You will also want someone who can guarantee that your information will be safe and secure - preferably using the same software that banks use to encrypt their data. Having no limit on the amount of emails to and from the company is also a nice benefit. Generic updates should be free.
The Kanban system was designed in the 1950's by a vice president of Toyota. It allows for trust in employees and management, reduces costs and allows for work sites that respond quickly to change. It allows workers to work to their maximum potential. It helps workers track small improvements that wind up rolling themselves into bigger overall improvements - which are easier for management to see using the graphs and charts of the Kanban system.
Most reputable website software companies will allow a free test period in which you try the software before you pay for it. After the grace period, the costs should be clearly laid out depending on how much you want the software to do. You can have as little as three hundred projects or as many as twelve hundred current tasks.
Finding Agile Project Management Software is worth the work. Finding a reputable company with which to do business is easy enough if you know what to ask about. Expect them to offer a wide range of project management software. Expect it to be easy to do - not requiring a computer science degree to work it. Expect the company to have adequate security - preferably the same security that banks use to encrypt their data. Finding software that works easily for you to track your employees' work makes everything so much simpler.
Click Here to visit WebTCards Ltd. to know more about agile project management software.


Call us at (334) 239-0875 or fill out this form. We'll contact you shortly to discuss your needs and ways to achieve your goals.
Let Sylvan of Montgomery give your child academic success today.
Tutoring starts at $38 per hour, Advancement classes & camps start at $45, and College Prep starts at $795.


Nobody plays music like Gerry Phillips, a man whose hands have been heard around the world.
"We had to keep reshooting because people kept laughing," recalls Jamieson. "We had to have silence on the set; there were a couple of young kids on the crew who we had to kick out of the studio. You could even hear the client—an American—struggling to keep it in all day." Melbourne's summer humidity meant Phillips had to change costumes regularly throughout the day to avoid visible sweat stains. Baby powder was a necessity, too, to keep his hands dry.
On a particularly cold winter's afternoon in 1914 in Traverse City, Michigan, a boy named Cecil Dill was walking home from school. His hands were cold, and since he had no mittens, he began pressing them together to produce some warmth. It didn't work, so he squeezed them tightly and was surprised to hear that this act allowed him to achieve a few different sounds. Intrigued, he began squeezing every day, until before long, he could play "Yankee Doodle" clear through, using only his hands.
Gerry Phillips saw Twomey's performance, too. "I thought I'd invented it, until 1974, when I saw a guy on Johnny Carson that could play," he says from his home in Troy, Michigan—coincidentally, the same state where both Cecil Dill and John Twomey began squeezing their hands together. Phillips's first encounter with this odd talent was at a children's birthday party, when a frustrated photographer made a noise with his hands to try to shut the kids up. It had the opposite effect on 9-year-old Gerry, who has been making his hand-noises ever since.
He uploaded his first video on Sept. 14, 2006, under the username "Gunecologist," which is apt, since he works at White's Gun Shop in Waterford, Michigan, a store his father bought in 1972. His first upload was a two-minute performance that he titled, in lower case, "manualist plays joy on his hands." The description is equally spare: "my name is gerry (jerry) phillips and i have been playing music on my hands for 38 years!" He sports a bushy mustache, a gold chain, and a sly smile while he sits on a floral couch, bouncing to the beat for couple of bars before enthusiastically reprising the song. A pair of speakers are set atop the couch behind him, and he wears a wireless microphone attached to a wristband to record audio.
Slowly, at first, the comments began to trickle in. "That is beyond weird…totally amazing, but weird. How did you learn you could do this?" wrote a user named SeraphsWings. "I'm blown away, that is truly a virtuoso performance," wrote dlbear. They weren't all positive, however. "You're pretty skilled at that. But I can't shake the feeling that you (literaly) have too much time on your hands," wrote WouterJ on Phillips's version of "Till There Was You" by the Beatles.
Over time, his recordings became more complex. Posted in March 2007, "Linus and Lucy (Peanuts Theme)" shows Phillips multitracking, and the result is a curious symphony of sound. His take on The Legend of Zelda theme relied on two Digitech guitar pedals—a whammy and a synth wah—to produce some extraordinary tones. That April he published "a manualist's tutorial or how to handfart!," which marked the first time he'd had spoken to the camera. "I don't know what else to tell you except try, and try, and try," he said near the end of the five-minute video. "I've been doing this for 37 years. It didn't take that long to be this good; I was this good when I was 13 or 14." Despite clearly showing how Phillips uses his huge hands to make sounds, though, he left a lot of the intricacies of his craft up to the viewers' imaginations. "This tutorial wasn't overly 'handy'," noted one commenter.
That single dose of thalidomide was enough to shape her son's anatomy in strange and unexpected ways, enlarging his hands while stunting his growth.
In 1959, when Phillips was in the womb, his mother used a drug thought to be a safe sedative for pregnant women. She hadn't slept in several days, and only took it once, but that single dose of thalidomide was enough to shape her son's anatomy in strange and unexpected ways. Thalidomide enlarged his hands while stunting his growth: His three older brothers are all around six-foot-two, whereas the youngest Phillips son is only five-foot-seven. "That's why people can't hold the notes and do the things I can do," says Phillips. "Their hands aren't even shaped like mine." He got off lightly compared to other thalidomide babies, some of whom suffered extreme birth defects, such as an Australian girl born without limbs.
The last television show he appeared on was You Have Been Warned; recently, the team from Outrageous Acts of Science dropped by his house to film. He regularly receives requests from talent shows around the world, and he's done children's television and morning radio. But he says he's turned down more opportunities than he's accepted. "The offers still come in," he says. "I'm just waiting for the right ones now that will make me happy, and that I'm interested in." What he's never done before is perform in front of a huge crowd. He would love to perform his manualism alongside the original musician at a big concert somewhere; several times, he mentions Brian May of Queen in this context.
Entertainment is a cutthroat business, and Phillips has no interest in playing what he sees as a demeaning game of fame-chasing, like appearing on a show like America's Got Talent to be judged by someone like Howie Mandel, for example. ("I don't find him very funny," Phillips says.) He's had plenty of fame, he says, and what he most appreciates is the praise from musicians whose work he's covered. And there's still that dream of performing with a band in front of 20,000 people. Just one song, even.
Andrew McMillen is a freelance journalist and author based in Brisbane, Australia.


1. 2 happy and healthy daughters who I love with all of my heart.
2. A husband I love and who loves me back.
3. Being at a place in life where I am happy... and look forward to more of the same.
4. A nice glass of wine and a piece of chocolate mint cream pie.
5. Being comfy and warm on the couch at midnight... wondering what the new year will bring.
Best wishes to all for a happy new year. May 2010 bring you everything you hope it will!


text:
Q: RegisterAllProvidersIP 1 or 0 For The Cluster Resource I have set up clustering across two sites, at each site there is a single instance of SQL 2014 enterprise and I am using Availability Groups.
I know I need to set RegisterAllProvidersIP for the AG Network name in order for the listener to check both IP Addresses.
One thing I'm not sure about is if I need to set RegisterAllProvidersIP for the actual cluster name??
Object Name Value Type

??????AG01_??????01 RegisterAllProvidersIP 1 UInt32
Object Name Value Type

Cluster Name RegisterAllProvidersIP 1 UInt32 <-----?????????????
Thanks in advance

A: I believe the RegisterAllProvidersIP is set to 1 automatically when you create the listener. With this setting, all subnets' IP addresses will be attached to the listener name. This is great, unless you're using older clients that do not support the MultiSubnetFailover option. If you do have such clients, you'll end up getting client connection timeouts (in our testing, we have 2 subnets and we'd get 50% connection timeouts).
To work around this (because we have fun legacy code), we set RegisterAllProvidersIP to 0 which only allows the primary node's IP address to register as the listener in DNS. The downfall of this is that we then had to understand DNS replication such that, in the event of a failover, the domain controller may not be in DNS cache (which relies on TTL for when to refresh) so the instance may not be available for a bit after failover, until the cache refreshes. We decided upon a 5 minute HostRecordTTL value (instead of the default 20 minutes) since our second subnet would only be used in a DR exercise or situation and that 5 minutes would be absorbed in the other DR activities.
At any rate, here is how you can get and set those values on the local machine:
Import-Module FailoverClusters
Get-ClusterResource {{name}} | Get-ClusterParameter

redpajama_set_name: RedPajamaStackExchange


text:
Home > Innovation > New Delhi witnessed More Than 800 Innovations under One Roof
New Delhi witnessed More Than 800 Innovations under One Roof
April 27, 2019 August 8, 2019 FutureTech
On 14th February 2019, New Delhi witnessed the inauguration of the 7thNational Level Exhibition and Project Competition (NLEPC) of the INSPIRE Awards – MANAK programme, which was inaugurated by Prof Ashutosh Sharma, Secretary, Department of Science and Technology, Government of India at IIT Delhi.
The National Capital witnessed more than 800 innovations under one roof as students from almost all States and Union Territories across the country had marched to the city so as to participate in a two – day 7th National Level Exhibition and Project Competition under INSPIRE Awards – MANAK scheme on 14th and 15th February, 2019.
The INSPIRE (Innovation in Science Pursuit for Inspired Research) Awards – MANAK(Million Minds Augmenting National Aspiration and Knowledge) is a flagship scheme of the Government of India, executed by the Department of Science and Technology (DST) and the National Innovation Foundation – India (NIF). Aligned with the action plan for "Start-up India" initiative, the scheme aims to help build a critical human resource pool for strengthening, expand science and technology system and increase the research & development base on the same by inviting students from all government and private schools throughout the country and enabling them to send their original & creative technological ideas/innovations on the same.
This year 2,87,994 ideas and innovations have been scouted with participation from all States and Union Territories of the country. Out of these, 50,279 were provided with a financial support of Rs 10,000 each for developing prototypes. After a series of DLEPC (District Level Exhibition and Project Competition) and subsequent SLEPC (State Level Exhibition and Project Competition) for those qualifying in DLEPC thereby covering more than 45000 innovations from nearly 650 districts, the stage is now set for NLEPC for those qualified in SLEPC. With the objective of bringing perfection to the prototypes being displayed by students, NIF conducted a series of mentoring workshops for students from 29 States in about two months at premier Technological Institutions of the country at 16 different locations.
The INSPIRE Awards – MANAK scheme is not just an award, rather it is a complete incubation programme where top ideas and innovations from NLEPC will be taken up for enterprise creation – suitable entrepreneurs will be scouted to take these innovations forward, entities will be incorporated and business operating models will be defined and executed.
On 15th February, 2019 an award function was held at Dogra Hall, IIT Delhi where top innovations participating in the National Level Exhibition and Project Competition (NLEPC) will be conferred with an award. In the award function 60 students got innovation awards.
The two-day exhibition was open for everyone to attend and all citizens were encouraged to visit and witness the innovation potential of India and benefit from it.
NIF, an autonomous body of the Department of Science and Technology, Government of India, has been actively engaged in promoting creativity and innovation in our society. NIF has taken major initiatives to serve the knowledge-rich common man of the country. It is committed to making India innovative by documenting, adding value, protecting the intellectual property rights (IPR) of the contemporary unaided technological innovators as well as of outstanding traditional knowledge-holders and disseminating their innovations on commercial and non-commercial basis.
By‑Dr Vipin Kumar
Director and Chief Innovation Officer
National Innovation Foundation ‑ India
Journey of a Student to Mentor
VUE: everyday smart glasses we always wanted

redpajama_set_name: RedPajamaCommonCrawl


Les Gelb, Karen Elliott House, and Professor Nubar Hovsepian discuss the recent airstrikes on Iraq.
Gelb, House, and Hovsepian on Iraq; bat conservationist Merlin Tuttle; Leon Botstein, president of Bard College.
A panel discusses whether or not the U.S. should have gone to war.
Nubar Hovsepian and Jonathan Jacoby discuss the Madrid Summit—a conference to broker peace between Israel and the Palestinian Authority.
Oliver North on Iran-Contra; Wilt Chamberlain on his memoir, "A View from Above"; Nubar Hovsepian and Jonathan Jacoby on the Madrid Summit.


Identifies whether one protein is druggable or not. DrugMiner has provided an opportunity for researchers to check if their own-synthesized proteins are druggable. It was developed by analyzing thousands of Drug-Protein interactions and users may provide their own protein Uniprot ID, protein name or protein sequence to customized target prediction. This tool has provided user-friendly approaches to mine druggable proteins within human proteins.
DrugMiner: comparative analysis of machine learning algorithms for prediction of potential druggable proteins.


text:
Anonymous. Our Settlement School Teachers. The University of Tennessee Libraries Digital Collections: From Pi Beta Phi to Arrowmont, 1914.
Anonymous. 3 students at the Pet Show. The University of Tennessee Libraries Digital Collections: From Pi Beta Phi to Arrowmont, 1925.
Anonymous. Mrs. Amos Reagan and family. The University of Tennessee Libraries Digital Collections: From Pi Beta Phi to Arrowmont, 1928.
Anonymous. War Emergency Finds Settlement School On The Alert. The University of Tennessee Libraries Digital Collections: From Pi Beta Phi to Arrowmont, 1942.
Anonymous. Delivering baskets - 1930.. The University of Tennessee Libraries Digital Collections: From Pi Beta Phi to Arrowmont, 1930.
Anonymous. Elderly Woman at Spinning Wheel at the Southern Highlands Craftsmans Fair.. The University of Tennessee Libraries Digital Collections: From Pi Beta Phi to Arrowmont, 1949.
Anonymous. Little Pigeon River valley.. The University of Tennessee Libraries Digital Collections: From Pi Beta Phi to Arrowmont, 1925.
Anonymous. A Gift from the Friends of the Mountain Children. The University of Tennessee Libraries Digital Collections: From Pi Beta Phi to Arrowmont, 1932.
Anonymous. Mary Francis Davidson. The University of Tennessee Libraries Digital Collections: From Pi Beta Phi to Arrowmont, 1975.
Anonymous. Boys on mules. The University of Tennessee Libraries Digital Collections: From Pi Beta Phi to Arrowmont, 1920.
Anonymous. A boy working with metal.. The University of Tennessee Libraries Digital Collections: From Pi Beta Phi to Arrowmont, 1995.
Anonymous. Rare snow storm.. The University of Tennessee Libraries Digital Collections: From Pi Beta Phi to Arrowmont, 1925.
Anonymous. "Another Lean-to Lost." Appalachian Trailway News 20, no. 1 (1959): 3.
Anonymous. Moon Handbooks. North Carolina. Avalon Travel Pub., 2003.
Anonymous. Summer School Metal and Jewelry Class.. The University of Tennessee Libraries Digital Collections: From Pi Beta Phi to Arrowmont, 1953.
Anonymous. Children's Painting. The University of Tennessee Libraries Digital Collections: From Pi Beta Phi to Arrowmont, 1995.
Anonymous. The Settlement School and its environs.. The University of Tennessee Libraries Digital Collections: From Pi Beta Phi to Arrowmont, 1920.
Anonymous. A Social History of the Scotch-Irish. Madison Books, 1993.
Anonymous. Baseball team.. The University of Tennessee Libraries Digital Collections: From Pi Beta Phi to Arrowmont, 1925.
Anonymous. "Fold-out Map: The Smokies. Facts and Legends about Our Most Popular National Park, Great Smoky Mountains." Backpacker 18, no. 6 (1990): 47.
Anonymous. One-Room Schoolhouse on Roaring Fork Road.. The University of Tennessee Libraries Digital Collections: From Pi Beta Phi to Arrowmont, 1920.
Anonymous. Students in front of One-Room Schoolhouse, Gatlinburg. The University of Tennessee Libraries Digital Collections: From Pi Beta Phi to Arrowmont, 1915.
Anonymous. Smoky Mountain Hymns, Featuring Hand-crafted Instruments. Brentwood Music, 1991.
"Llamas: Exotic Trail Packing." National Parks 59, no. 3-4 (1985): 30-31.
"Smokies Road Problem Again." National Parks 35, no. 153 (1960): 15.


Oberman Law Firm proudly announces our continued support of the Georgia Society of Oral and Maxillofacial Surgeons. This year, Oberman Law Firm will participate as an exhibitor in the 2019 GSOMS Summer Meeting from August 9-11, 2019 at the Ritz Carlton of Lake Oconee. Oberman Law Firm proudly supports continued education in the oral surgery field, and we look forward to another wonderful meeting this year.


Tic Tac Toe's not just for Xs and Os. Why not have a TicTac Toe game going as an opening activity that helps set the stage for your lesson? Here, our own, Louise, used a paper plate as the game board with flower buttons verses seeds (or beans) in a garden version of the game helpful in setting the stage for a lesson of the Garden of Eden or Jesus' Prayers in the Garden of Gethsemane.
You could use use other items to set your stage. You could use US pennies and a foreign coin (or plastic play money) before you discuss the money changers in the temple.
Or maybe you could cut some small shapes add glue and glitter to one set and sand to another set. You'd have grains of sand verses stars in the sky to illustrate a lesson on Abraham.
Feel free to share other ways you can shake up a game of Tic Tac Toe!


text:
#include <Furrovine++/Graphics/Dx/Platform.Enums.Dx.h>
#include <Furrovine++/Graphics/graphics_handle.h>
#include <Furrovine++/Graphics/Declarations.Graphics.h>
#include <Furrovine++/Graphics/Texture1DDescription.h>
#include <Furrovine++/Graphics/Texture2DDescription.h>
#include <Furrovine++/Graphics/Texture3DDescription.h>
#include <Furrovine++/Graphics/MultisampleDescription.h>
#include <Furrovine++/Graphics/DepthStencilBufferDescription.h>
#include <Furrovine++/Graphics/DepthStencilBufferDescription.h>
#include <Furrovine++/Graphics/GpuBufferDescription.h>
#include <Furrovine++/Graphics/DisplayModeDescription.h>
#include <Furrovine++/Graphics/AdapterDescription.h>
#include <Furrovine++/Graphics/AdapterOutputDescription.h>
#include <Furrovine++/Graphics/SubresourceData.h>
#include <Furrovine++/Graphics/VertexElement.h>
#include <Furrovine++/Graphics/SamplerStateDescription.h>
#include <Furrovine++/Graphics/BlendStateDescription.h>
#include <Furrovine++/Graphics/BlendStateCollectionDescription.h>
#include <Furrovine++/Graphics/RasterizerStateDescription.h>
#include <Furrovine++/Graphics/DepthStencilStateDescription.h>
#include <Furrovine++/Graphics/ShaderVariableDescription.h>
#include <Furrovine++/Graphics/ShaderResourceDescription.h>
#include <Furrovine++/Graphics/ShaderVariableTypeDescription.h>
#include <Furrovine++/Graphics/ShaderBufferDescription.h>
#include <Furrovine++/rational.h>

namespace Furrovine { namespace Graphics { namespace Dx {

#ifdef FURROVINEDIRECTX

	furrovineapi Rectangle FromPlatform( const RECT& rect );

	furrovineapi rational<uint32> FromPlatform( const DXGI_RATIONAL& plat );

	furrovineapi MultisampleDescription FromPlatform( const DXGI_SAMPLE_DESC& desc );

	furrovineapi D3D11_TEXTURE1D_DESC ToPlatform( const Texture1DDescription& value );

	furrovineapi DXGI_SAMPLE_DESC ToPlatform( const MultisampleDescription& value );

	furrovineapi D3D11_TEXTURE2D_DESC ToPlatform( const Texture2DDescription& value );

	furrovineapi D3D11_TEXTURE2D_DESC ToPlatform( Graphics::SurfaceFormat, const DepthStencilBufferDescription& value );

	furrovineapi D3D11_TEXTURE2D_DESC ToPlatform( Graphics::DepthStencilFormat, const DepthStencilBufferDescription& value );

	furrovineapi D3D11_TEXTURE2D_DESC ToPlatform( const DepthStencilBufferDescription& value );

	furrovineapi D3D11_TEXTURE3D_DESC ToPlatform( const Texture3DDescription& value );

	furrovineapi DXGI_RATIONAL ToPlatform( const rational<uint32>& value );

	furrovineapi D3D11_BUFFER_DESC ToPlatform( const GpuBufferDescription& value );

	furrovineapi DXGI_MODE_DESC ToPlatform( const DisplayModeDescription& mode );

	furrovineapi D3D11_SUBRESOURCE_DATA ToPlatform( const SubresourceData& value );

	furrovineapi D3D11_INPUT_ELEMENT_DESC ToPlatform( const VertexElement& value );

	furrovineapi D3D11_SAMPLER_DESC ToPlatform( const SamplerStateDescription& value );

	furrovineapi D3D11_RASTERIZER_DESC ToPlatform( const RasterizerStateDescription& value );

	furrovineapi D3D11_DEPTH_STENCILOP_DESC ToPlatform( const StencilOperationDescription& value );

	furrovineapi D3D11_DEPTH_STENCIL_DESC ToPlatform( const DepthStencilStateDescription& value );

	furrovineapi D3D11_RENDER_TARGET_BLEND_DESC ToPlatform( const BlendStateDescription& value );

	furrovineapi D3D11_BLEND_DESC ToPlatform( const BlendStateCollectionDescription& value );

	furrovineapi Texture1DDescription FromPlatform( const D3D11_TEXTURE1D_DESC& desc );

	furrovineapi Texture2DDescription FromPlatform( const D3D11_TEXTURE2D_DESC& desc );

	furrovineapi Texture3DDescription FromPlatform( const D3D11_TEXTURE3D_DESC& desc );

	furrovineapi AdapterOutputDescription FromPlatform( const DXGI_OUTPUT_DESC& desc );

	furrovineapi AdapterDescription FromPlatform( const DXGI_ADAPTER_DESC& desc );

	furrovineapi VertexElement FromPlatform( const D3D11_INPUT_ELEMENT_DESC& desc );

	furrovineapi VertexElement FromPlatform( const D3D11_INPUT_ELEMENT_DESC& desc, VertexElementComponent component, uint32 componentcount );

	furrovineapi SamplerStateDescription FromPlatform( const D3D11_SAMPLER_DESC& desc );

	furrovineapi RasterizerStateDescription FromPlatform( const D3D11_RASTERIZER_DESC& desc );

	furrovineapi BlendStateDescription FromPlatform( const D3D11_RENDER_TARGET_BLEND_DESC& desc );

	furrovineapi BlendStateCollectionDescription FromPlatform( const D3D11_BLEND_DESC& desc );

	furrovineapi StencilOperationDescription FromPlatform( const D3D11_DEPTH_STENCILOP_DESC& desc );

	furrovineapi DepthStencilStateDescription FromPlatform( const D3D11_DEPTH_STENCIL_DESC& desc );

	furrovineapi ShaderVariableDescription FromPlatform( const D3D11_SHADER_VARIABLE_DESC& desc );

	furrovineapi ShaderVariableTypeDescription FromPlatform( const D3D11_SHADER_TYPE_DESC& desc );

	furrovineapi ShaderBufferDescription FromPlatform( const D3D11_SHADER_BUFFER_DESC& desc );

	furrovineapi ShaderResourceDescription FromPlatform( const D3D11_SHADER_INPUT_BIND_DESC& desc );

	furrovineapi DisplayModeDescription FromPlatform( const DXGI_MODE_DESC& desc );

	furrovineapi std::pair<uint32, std::vector<VertexElement>> CreateVertexElements( graphics_handle reflectionresource, bool output = false );

#endif // DIRECTX

}}}

redpajama_set_name: RedPajamaGithub


Preached by Canon Mark Collinson using Isiah 63:7-15 and 1 Corinthians 10:1-13 at Mattins on Sunday 15th April 2018, the Third Sunday of Easter.
One of the things that I find rather strange about cathedral services (and the same is true for church services) is the way work our way through the order of service – our script every Sunday! We say or sing such an assortment of readings and songs that were written in different languages and relate to five different millennia – and we assume that they all make sense without further explanation. What is happening in our service of worship today, as in any other day, is we are interweaving a series of historical stories and songs from the past into the narrative of our own lives.
It's a bit like a novel I remember reading a long time ago by the Peruvian writer, Mario Vargas Llosa, called Aunt Julia and the Scriptwriter. In the novel the main character is a scriptwriter who writes and stars in soap operas for radio.
His scripts are so realistic and reflect his own life so much that by the end of the book his own life is completely interwoven with the scripts of the soap operas. The reader gets completely lost – because it is no longer possible to distinguish the scriptwriter's own life from the stories he is creating. In the final chapter we find out that the main character is the author himself.
That's something like what is happening to Christians when they gather for worship. We are interweaving the narrative of salvation history into our own lives, so that His story becomes our story, the story of God revealing himself to all of humanity.
So how might we make sense of the stories we've heard this morning?
Our Old Testament reading from the book of Isaiah, relates to around the 6th century before Christ. Incidentally, I read recently that a seal has been found near the Temple Mount in Jerusalem that dates to the time of King Hezekiah, and it has Isaiah's name on it, providing, for the first time, a possible piece of archeological evidence that Isaiah was indeed a trusted prophet of the King.
The latter part of the book, the 63rd chapter, reflects a later period than Hezekiah, around 520 BC, a period after what is known as the exile. The exile occurred when the Babylonian Empire deported the ruling classes, the intellectuals and the wealthy.
This was interpreted as God's punishment on Israel for not being faithful to God.
because of all that the Lord has done for us.
Then the prophet remembers what it was like nearly 900 years previously, when God showed his faithfulness to Moses, who led the people of Israel from slavery in Egypt to freedom in the Promised Land.
Those were the days when God was a Saviour to his people. So you see that in the Old Testament text, the prophet is calling his contempories to remember the past, to shape their lives by remembering the accounts of God's faithfulness to their ancestors at the time of Moses.
Our New Testament reading does something similar. Corinthians is a letter written by the apostle Paul to Christians in the Greek city of Corinth about 2,000 years ago, in the first century. Paul is telling them about a story from a different culture and and a different time.
He also refers to the time of Moses who lived around 1,400 years before Christ.
So Paul does the same thing as we see happening in Isaiah 63: he wants his listeners, who are from a completely different culture, in a different country, who speak a different language, to look back and have their lives shaped by this ancient story of the salvation of Moses. Paul says that the spiritual ancestors of the Greek speaking Corinthians, are the people of Israel, whom God saved from slavery in Egypt, and they too may shape their lives by the story of Moses.
But here's the really fascinating bit: the impact of the resurrection of Jesus.
I imagine the first disciples two Sundays after seeing Jesus risen from the dead, are twisting their minds to understand what God is doing and what Jesus' resurrection means. It's as if the whole world has been turned upside down and they're trying to make sense of it.
Paul is writing to Corinth having had at least 17 years of reflecting on the resurrection of Christ. And he says, 'For they [the Israelites in the wilderness at the time of Moses] drank from the spiritual rock that followed them, and the rock was Christ.' (1 Cor 10:3). He sees how the story of the pre-incarnate Son of God, connects with the story of Moses. In the desert it wasn't just God who was giving them the water of life, God was giving them the life of Christ.
These weeks of the Easter season is a period when we, in the third millennium after Christ, re-evaluate our lives in the light of the resurrection of Christ.
Like the first disciples who struggled to believe that they were seeing the risen Jesus in bodily form, we re-read the stories of God's faithfulness to his people and we begin to see Christ's presence being interwoven in our own lives.
I happen to be celebrating my 50th birthday today and it has been a joy to gather people this weekend from all the previous five decades of my life. It has been a weekend of sober reflection – of recognising the inevitability of being unable to deny that I am middle-aged!
But in every decade of my life I can perceive the hand and voice of God influencing, guiding, whispering and encouraging me to deny myself and to follow Christ. I can no longer tell my story without relating it to the story of Jesus Christ, who was born, lived, died and rose again 2,000 years ago. I've been learning my script in God's story.
But going back 2,000 years ago to the resurrection, is not going back far enough. My own life, like every human life, goes back to the salvation that Moses brought, and before that to very creation itself, because every human being is made in the likeness of God, in likeness of Jesus Christ.
Being a Christian, and coming here to worship on a Sunday morning, we begin to realise, I hope, that we are not the main character in the story of our lives.
The main character is God, Father, Son and Holy Spirit, who birthed us, who formed us and shaped us, who has been speaking to us since before we were born, and who reveals himself to us. He calls all humanity to find fulfilment in his story. Our lives are not about writing our own script, our own story; every Sunday morning in cathedral or church, we are learning the lines of God's story and finding out where we play our part.


The HPE ProLiant DL120 G7 server is an entry-level rack-optimized server providing user with all the confidence of an HPE ProLiant server. The single processor, 1U server is ideal for single-application IT infrastructure, web and edge-of-network applications. The HPE ProLiant DL120 provides two PCI express slots with optional upgrades, including HPE HBAs and smart array controllers, which provide support for SAS hard disk drives. The DL120 G7 supports HPE Integrated Lights-Out 3 (iLO 3) remote management which provides cost-effective remote management from anywhere, anytime. Plus, user get the cost-effective solution of a single-processor platform with the performance advantages of quad-core technology.
NOTE: 1: Available through configure to order only. See factory integration models section for more details.
HT indicates that the processor model supports Intel Hyper-Threading technology.
Turbo indicates the maximum potential frequency increment when using Intel turbo boost technology, with 4, 3, 2, and 1 cores are active.
DDR3 speed is the maximum memory speed of the processor. Actual memory speed may depend on the quantity and type of DIMMs installed.
2: Depending on the memory configuration and processor model, the memory speed may run at 1333 MHz or 1066 MHz. Click here to view the Online Memory Configuration Tool .
3: Bus number: Default bus assignment (In decimal). Inserting cards with PCI bridges may alter the actual bus assignment number.
Device no: Slots are enumerated differently based on OS. MS OS's enumerate from lowest to highest Device IDby bus (Starting with the lowest bus).
Buswidth: Indicates the number of physical electrical lanes running to a PCI-e connector.
SATA hot plug available VIA hot plug advance pack for B110i.
Available upgrade: HPE Smart Array hot plug advance pack forB110i.
5: Available upgrades: Battery kit upgrade (For BBWC), and Smart Array Advanced Pack (SAAP).
6: SAS requires optional HBA or SA card.
SATA hot plug functionality available VIA hot plug advance pack for B110i.
8: This is shared NIC port for iLO. If users do not purchase iLO dedicated NIC option card they can still use this port as shared NIC Port.
9: Internal USB port (Optional) for flexible storage, security, or USB drive key deployment.
Click here to access the HPE ProLiant DL120 G7 Server Worldwide QuickSpecs in html format .
Click here to access the HPE ProLiant DL120 G7 Server Worldwide QuickSpecs in pdf format .


Want the swatch sheet? Get it here: https://gum.co/PamEFi My Shop! http://bit.ly/2wpGqpR ↓ Everything you want to know is down here! ↓ Just a fun day at the zoo! | For more in depth information, go to my blog post: ★YOU can help me make more videos!★ For behind the scenes updates, exclusive reference photos, tutorials, and secret hangouts, support my work on Patreon! https://www.patreon.com/sadiesavestheday Thanks for watching! · · · · · · Did you like the video? Want more speedpaints, tutorials, and art supply reviews? Subscribe to my channel! - http://bit.ly/23dTSSz Contribute Subtitles Here: http://www.youtube.com/timedtext_cs_panel?tab=2&c=UCtTQbFqjapIrCgtm3BGzvcg If you have any questions or comments, leave them below! Don't forget to leave a thumbs up. :) · · · · · · Materials: Check out my Amazon wishlist!: http://amzn.to/2pxqDhZ Get the supplies I love to use! : https://kit.com/Sadiesavestheday/watercolor-art-supplies · · · · · · Shop! Originals | https://www.sadiesavestheday.com/original-artwork/ Prints | https://www.sadiesavestheday.com/prints/ Commission Me | https://www.sadiesavestheday.com/custom/ Watercolor Templates | https://www.sadiesavestheday.com/digital-products/ Courses and Tutorials | https://www.sadiesavestheday.com/courses/ · · · · · · Want to keep in touch? Connect with me below! Patreon | https://www.patreon.com/sadiesavestheday Website | http://www.sadiesavestheday.com/blog/ Instagram | http://instagram.com/sadiesavestheday Twitter | https://twitter.com/sadiesavesit Pinterest | https://www.pinterest.com/sadiesavestheda/ Facebook | https://www.facebook.com/sadiesavestheday Tumblr | http://sadiesavestheday.tumblr.com/ · · · · · · Music:Lee Rosevere "" - (Creative Commons license: https://creativecommons.org/licenses/by/3.0/) · · · · · · Some of the links above may include affiliate links. If you click on them, I might receive a small commission. While this is at absolutely no additional cost to you, your support can help me to continue making videos for this channel. Thanks!
Am 6. Juni 1994 wurde im Dresdner Norden der Grundstein für ein hochmodernes Halbleiterwerk gelegt. Der Dresdner Unternehmensstandort hat in den vergangenen zwei Jahrzehnten immer wieder neue Maßstäbe gesetzt: So entstand hier 1994 die modernste Halbleiterfabrik in Europa. Im Jahr 2000 wurde in Dresden der Grundstein für die weltweit erste Fabrik gelegt, die auf 300-mm großen Siliziumscheiben (Wafern) produziert. Heute baut Infineon in Dresden die weltweit erste Hochvolumen-Fertigung für Leistungshalbleiter auf 300-mm-Dünnwafern auf. Infineon Dresden blickt, 20 Jahre nach der Grundsteinlegung, als eine der modernsten Fertigungen weltweit in eine positive Zukunft.
National Archives and Records Administration - ARC 39158, LI 208-UN-1041 - Series: Motion Picture Films from "United News" Newsreels, compiled 1942 - 1945. Part 1, hordes of British and 8th Air Force planes bomb Dresden by day and night. Part 2, Paris and other French towns are flooded. Part 3, Gen. de Gaulle decorates French and U.S. soldiers, including Generals Devers and Patch, in celebration of the triumph at Colmar. Part 4 shows Churchill and Field Marshall Alexander in Athens. Part 5, allied troops advance in Germany. Soldiers cross a river under a smoke screen.
Infineon Technologies - 20 Jahre Standort Dresden, eine Geschichte mit Zukunft. Einblicke in die Jubilarfeier am 6. Juni 2014.
http://www.mdr.de/comedymitkarsten/slam-poetry-meisterschaft-in-dresden102.html Sieg für "Alter Schwede" bei den Deutschen Poetry Slam Meisterschaften in Dresden! In einem spannenden Stechen setzte sich der Hesse von "Kreuzbergslam Berlin" am Ende im Einzelwettbewerb gegen Paul Weigl (2. Platz) und Tobias Gralke (3. Platz) durch. Das Einzelfinale gibt's am 26.11.2014 um 00.35 Uhr noch einmal im MDR FERNSEHEN zu sehen, das Team-Finale dann am 03.12.2014 um 00.35 Uhr.
Electrician from BSD-Dresden demonstrating method for jointing onto an old oil/paper insulated 3-core cable, with a new 4-core aluminium cable (plastic insulation). The main cable has 230 V AC applied throughout the jointing operation.
Dresden is a town in Lincoln County, Maine, United States that was incorporated in 1794. The population was 1,672 at the 2010 census.
The town was originally settled in 1752 under the name Frankfort by French and German Huguenots, who were part of the first wave of French speaking immigrants to arrive in Maine, but were distinguished from later arrivals by their Protestant faith. William Shirley built Fort Shirley in the community at the same time Fort Halifax (Maine) was built. First called Frankfort, so that the new French immigrants could pretend to be German, the town was incorporated as Pownalborough in 1760, when Lincoln County was created in the Maine District of Massachusetts. Pownalborough included the Town of Wiscasset, which was soon set off on its own as the shire town of the county. When the present territory was incorporated in 1794, Lincoln County Probate Judge Jonathan Bowman chose Dresden as the new name of the town because he liked the sound of it.
Dresden is located on the eastern side of the Kennebec River. Dresden also offers some historical sites as well, including an old, brick school building and the Pownalborough Courthouse, which is now used as a museum and is open to the public. The Pownalborough Courthouse was built in 1760 and was the first seat of government east of the Kennebec River. The families who settled Dresden and those who were soon afterward sent there by the government of Massachusetts played a crucial role in the battle for American independence in Maine. Robert Treat Paine, John Hancock, and John Adams appeared at the Court House in the Revolutionary Era. Well known local families included the Goodwins, Houdlettes, Mayerses, Bridges, Bowmans, Percys, Johnsons, and Trussells, who variously left their marks on the history of the town, the state, and the country.
Infineon Technologies AG is a German semiconductor manufacturer founded on 1 April 1999, when the semiconductor operations of the parent company Siemens AG were spun off to form a separate legal entity. As of 30 September 2013, Infineon has 26,725 employees worldwide. In fiscal year 2013, the company achieved sales of €3.843 billion.
On 1 May 2006, Infineon's Memory Products division was carved out as a distinct company called Qimonda AG, which at its height employed about 13,500 people worldwide. Qimonda was listed on the New York Stock Exchange until 2009.
Infineon Technologies AG, in Neubiberg near Munich, offers semiconductors and systems for automotive, industrial, and multimarket sectors, as well as chipcard and security products. With a global presence, Infineon operates through its subsidiaries in the USA, from Milpitas, California, and in the Asia-Pacific region, from Singapore and from Tokyo, Japan.
Infineon has a number of facilities in Europe, one in Dresden, Germany, Europe's microelectronic, and emerging technologies center. Infineon's high power segment is in Warstein, Germany; Villach and Graz in Austria; Cegléd in Hungary; and Italy. It also runs R&D centers in France, Singapore, Romania, Taiwan, UK and India, as well as fabrication units in Singapore, Malaysia, Indonesia, and China. There's also a Shared Service Center in Maia, Portugal.


text:
The Top CIRM Blogs of 2019
January 2, 2020 / Kevin McCormack	/ Leave a comment
This year the most widely read blog was actually one we wrote back in 2018. It's the transcript of a Facebook Live: "Ask the Stem Cell Team" event about strokes and stroke recovery. Because stroke is the third leading cause of death and disability in the US it's probably no surprise this blog has lasting power. So many people are hoping that stem cells will help them recover from a stroke.
But of the blogs that we wrote and posted this year there's a really interesting mix of topics.
The most read 2019 blog was about a potential breakthrough in the search for a treatment for type 1 diabetes (T1D). Two researchers at UC San Francisco, Dr. Matthias Hebrok and Dr. Gopika Nair developed a new method of replacing the insulin-producing cells in the pancreas that are destroyed by type 1 diabetes.
Dr. Matthias Hebrok
Dr. Gopika Nair
Dr. Hebrok described it as a big advance saying: "We can now generate insulin-producing cells that look and act a lot like the pancreatic beta cells you and I have in our bodies. This is a critical step towards our goal of creating cells that could be transplanted into patients with diabetes."
It's not too surprising a blog about type 1 diabetes was at the top. This condition affects around 1.25 million Americans, a huge audience for any potential breakthrough. However, the blog that was the second most read is the exact opposite. It is about a rare disease called cystinosis. How rare? Well, there are only around 500 children and young adults in the US, and just 2,000 worldwide diagnosed with this condition.
It might be rare but its impact is devastating. A genetic mutation means children with this condition lack the ability to clear an amino acid – cysteine – from their body. The buildup of cysteine leads to damage to the kidneys, eyes, liver, muscles, pancreas and brain.
Dr. Stephanie Cherqui
UC San Diego researcher Dr. Stephanie Cherqui and her team are taking the patient's own blood stem cells and, in the lab, genetically re-engineering them to correct the mutation, then returning the cells to the patient. It's hoped this will create a new, healthy blood system free of the disease.
Dr. Cherqui says if it works, this could help not just people with cystinosis but a wide array of other disorders: "We were thrilled that the stem cells and gene therapy worked so well to prevent tissue degeneration in the mouse model of cystinosis. This discovery opened new perspectives in regenerative medicine and in the application to other genetic disorders. Our findings may deliver a completely new paradigm for the treatment of a wide assortment of diseases including kidney and other genetic disorders."
Sickled cells
The third most read blog was about another rare disease, but one that has been getting a lot of media attention this past year. Sickle cell disease affects around 100,000 Americans, mostly African Americans. In November the Food and Drug Administration (FDA) approved Oxbryta, a new therapy that reduces the likelihood of blood cells becoming sickle shaped and clumping together – causing blockages in blood vessels.
But our blog focused on a stem cell approach that aims to cure the disease altogether. In many ways the researchers in this story are using a very similar approach to the one Dr. Cherqui is using for cystinosis. Genetically correcting the mutation that causes the problem, creating a new, healthy blood system free of the sickle shaped blood cells.
Two other blogs deserve honorable mentions here as well. The first is the story of James O'Brien who lost the sight in his right eye when he was 18 years old and now, 25 years later, has had it restored thanks to stem cells.
The fifth most popular blog of the year was another one about type 1 diabetes. This piece focused on the news that the CIRM Board had awarded more than $11 million to Dr. Peter Stock at UC San Francisco for a clinical trial for T1D. His approach is transplanting donor pancreatic islets and parathyroid glands into patients, hoping this will restore the person's ability to create their own insulin and control the disease.
2019 was certainly a busy year for CIRM. We are hoping that 2020 will prove equally busy and give us many new advances to write about. You will find them all here, on The Stem Cellar.
CIRM's Alpha Stem Cell Clinics Given High Profile Role in Clinical Trials Network
December 13, 2019 / Kevin McCormack	/ Leave a comment
Sue and Bill Gross Hall Photo by Hoang Xuan Pham/ UC Irvine
There are a growing number of predatory clinics in California and around the US, offering unproven stem cell therapies. For patients seeking a legitimate therapy it can often be hard finding a reliable clinic, one offering treatments based on the rigorous science required in a clinical trial sanctioned by the US Food and Drug Administration (FDA). That's one of the reasons why the California Institute for Regenerative Medicine (CIRM) created the CIRM Alpha Stem Cell Clinic Network and we are delighted the clinics have now been chosen as a Core program of the American Society of Hematology (ASH) Sickle Cell Disease (SCD) Collaborative Trials Network.
The Alpha Clinics are a network of top California medical centers that specialize in delivering stem cell clinical trials to patients. It consists of five leading medical centers throughout California: City of Hope, University of California (UC) San Diego, UC Irvine & UC Los Angeles, UC Davis and UC San Francisco.
The mission of the ASH Research Collaborative SCD Clinical Trials Network is to improve outcomes for individuals with Sickle Cell Disease by promoting innovation in therapy development and clinical trial research.
Like CIRM, the ASH Clinical Trials Network is a member of the National Heart, Lung and Blood Institute's Cure Sickle Cell Initiative. This is a collaborative partnership to accelerate the development of genetic therapies to cure SCD within five to ten years.
"The key to finding a cure for this crippling disease, and finding it quickly, is to work together", says Maria T. Millan, MD, President & CEO of CIRM. "That's why we are delighted to be chosen as a core program for the ASH Sickle Cell Disease Clinical Trials Network. This partnership means we can share data and information about best practices to help us improve the quality of the research being done and the clinical care we can offer patients. We already have 23 clinical stage therapies in cell and gene therapy, including two clinical trials targeting SCD, so we feel we have a lot to bring to the partnership in terms of experience and expertise."
Sickle Cell disease is a life-threatening blood disorder that affects 100,000 people, mostly African Americans, in the US. It is caused by a single genetic mutation that results in the production of "sickle" shaped red blood cells that can block blood vessels causing intense pain, recurrent hospitalization, multi-organ damage and strokes.
According to Mark Walters, MD, Director of UCSF Benioff Children's Hospital Oakland's Blood and Marrow Transplantation program, "the currently available drugs treat the symptoms of sickle cell disease but are not a cure.
"We hear a lot about the moonshot for curing cancer, but a moonshot for curing sickle cell disease should also be possible. Sickle cell disease was the first genetic disease that was discovered, and wouldn't it be great if it is also one of the first ones we can cure in everyone?"
It is hoped that creating this network of clinical trial sites across the US will better serve an historically under-served population.
Establishing links and educational materials across these sites can increase patient engagement and recruitment
Standardizing resources across the network can ensure efficiency and coordination
Improving the training of clinical research staff can promote patient safety and trust and increase research quality
The CIRM Alpha Clinics Network has a proven track record of creating a faster, more streamlined approach in running clinical trials. It has developed the tools and systems to simultaneously launch clinical trials at multiple sites; created model non-disclosure agreements to make it easier for clinical trial sponsors to sign up; created a system to enable one Institutional Review Board (IRB) to approve a trial to be carried out at multiple sites rather than requiring each site to have its own IRB approval; developed best practices to quickly share experience and expertise across the network; and set up a database of over 20 million Californians to improve patient recruitment.
An Executive Summary prepared for the Western States Sickle Cell Disease Clinical Trials Network said: "the ASCC provides a formidable clinical trial unit uniquely qualified to deliver the next generation of cell and gene therapy products for SCD."
What would you like to know about stem cell research? This is your chance to ask the experts.
November 14, 2019 / Kevin McCormack	/ 4 Comments
There's a lot of fiction, a lot of misinformation surrounding stem cells and stem cell research. There are claims that are not based on solid science and clinics that are offering so-called "treatments" that are unproven, even dangerous for patients. Now you have a chance to talk to the experts in the field and get solid answers from them about what's working, what's not, and how you can find a therapy that might be appropriate for you.
Do you have questions about the latest in research using stem cells to help people recovering from a stroke? We'll have someone who can answer them.
Want to know if stem cells can help people battling cancer? Or what's happening in finding a stem cell treatment for diabetes or sickle cell disease, even autism, Alzheimer's or Parkinson's disease? We'll have experts to answers those.
This is all happening in a special Facebook Live "Ask the Stem Cell Team" event on Thursday, December 12th from 10.30am to 11.30am PDT. To take part all you have to do is tune in on the day and post a question or you can send us one ahead of time at info@cirm.ca.gov
We will do our best to answer as many of them as we can during the Facebook Live event, and those we don't have time to get to we'll answer in a blog at a later date.
So join us.
Rare disease meeting at California Capitol stresses importance of advocacy, funding, and new research
September 3, 2019 September 3, 2019 / Yimy Villa	/ Leave a comment
Dr. Martin Cadeiras (far left), who specializes in cardiovascular medicine at UC Davis, discusses the rare disease amyloidosis. Next to Dr. Cadeiras is Len Strickland, a patient advocates who shares his perspective on living with the disease.
"By changing policy, we can change lives"
A powerful opening statement by Angela Ramirez Holmes, Founder & President of the California Action Link for Rare Diseases (CAL RARE).
Tuesday of last week, patient advocates, patient advocacy organizations, and members of the public filled a room at the California Capitol for an informational hearing on research related to rare diseases. One of the organizations present was CAL RARE, a non-profit organization that is dedicated to improving the lives of California patients with rare diseases. Angela's opening statement reflects CAL RARE's core mission of bringing awareness of rare diseases to the general public and decision makers in order to improve access to physicians, treatments, and social services.
Dr. Martin Cadeiras
One of the first presenters was Dr. Martin Cadeiras from the Department of Cardiovascular Medicine at UC Davis. His presentation focused on a rare disease named amyloidosis, which occurs when a protein called amyloid builds up in the body's organs and tissues. This can lead to problems in the heart, skin, kidneys, liver, and digestive tract. There are several different types of amyloidosis, one of which is hereditary and another form that can occur after chronic infection. Dr. Cadeiras spoke in detail about the scientific complexities behind amyloidosis and shared images of patients affected with the disease as well as the complications associated with their condition.
Len Strickland
To elaborate more on the patient perspective of this disease, patient advocate Len Strickland shared his journey living with amyloidosis. In addition to living with the disease, Len also has the sickle cell trait, meaning he has one copy of the sickle cell disease gene but one normal copy.
In his early life, Len was a typical young adult with no health problems. Unfortunately for him that changed in 2006, when he started having problems with shortness of breath and heart palpitations almost overnight. He visited many doctors, all of which were perplexed by his condition and were unable to diagnose him.
"My normal life was gone, and I was very concerned." said Strickland.
One year later, after multiple tests and specialists, he was finally diagnosed with the hereditary version of amyloidosis. As a result of his condition, he was in dire need of a heart transplant. On March 4, 2008 he was placed on the transplant list. Because he was relatively lower on the priority list, he was told to keep hope to a minimum. Fortunately, on June 10, 2008 a matching donor heart was found and by the next day, Len had successfully received the heart transplant.
Len wrote a thank you letter to the mother of the deceased donor and regularly keeps in touch with her. She hopes to one day meet Len in person so that she can hug Len and hear her son's heartbeat.
Although the amyloid deposits have spread to Len's hand and feet, he is still able to live his life.
Len ended his speech by telling the crowd,
"Make the best of the time you have, if I can do it, so can you."
Dr. Lauge Farnaes
The challenges Len faced with getting a proper diagnosis brought up the need for technology that can better screen rare diseases. The next presenter, Dr. Lauge Farnaes of Rady Children's Institute for Genomic Medicine, discussed a project that focused on just that. Under a two million dollar Medi-Cal program titled Project Baby Bear, Dr. Farnaes and his team have used genome sequencing as a diagnostic test for critically ill newborns. The ultimate goal is to get this screening as a Medi-Cal covered benefit.
Comprehensive early testing enables physicians to make early decisions about and minimize the damage accumulated before diagnosis. "We have a chance to go in early on and make a difference in the life of patients." said Farnaes.
Dr. Farnaes told stories of some of the children enrolled in the screening program. One was a young girl that had problems related to the heart. She was enrolled February 6th and diagnosed two days later with Timothy Syndrome, making her one of the youngest patients ever diagnosed. She was implanted with a defibrillator to help with her heart problems. Dr. Farnaes had stated that without the screening, she would have likely just been prescribed beta blockers, which would only have worsened her condition.
Another child enrolled in the program had difficulty breathing as a result of bone fractures. Because of the bone fractures, it was thought that the child had undergone abuse at the hands of the parents. However, thanks to the screening technology, it was found to be the result of a genetic condition. Dr. Farnaes talked about how this technology vindicated the parents, who were already going through the difficult process of having a sick child without throwing other problems into the mix.
To date, 116 children have been diagnosed with genetic conditions early on using this technology and the number is expected to eventually approach 150.
Last, but not least, Assemblymember Mike Gipson shared an update on the work that the rare disease caucus has made with relation to sickle cell disease. He mentioned how the legislative black caucus had successfully advocated for allocating $15 million for sickle cell disease. This money will be used to open seven new sickle cell centers across California.
The meeting in the California Capitol highlighted the impact that patient stories have on policy, as well as the ongoing need of funding and new technologies to address the disparities in rare disease.
From bench to bedside: a Q&A with stem cell expert Jan Nolta
July 19, 2019 / Kevin McCormack	/ Leave a comment
At CIRM we are privileged to work with many remarkable people who combine brilliance, compassion and commitment to their search for new therapies to help people in need. One of those who certainly fits that description is UC Davis' Jan Nolta.
This week the UC Davis Newsroom posted a great interview with Jan. Rather than try and summarize what she says I thought it would be better to let her talk for herself.
Jan Nolta
Talking research, unscrupulous clinics, and sustaining the momentum
(SACRAMENTO) —
In 2007, Jan Nolta returned to Northern California from St. Louis to lead what was at the time UC Davis' brand-new stem cell program. As director of the UC Davis Stem Cell Program and the Institute for Regenerative Cures, she has overseen the opening of the institute, more than $140 million in research grants, and dozens upon dozens of research studies. She recently sat down to answer some questions about regenerative medicine and all the work taking place at UC Davis Health.
Q: Turning stem cells into cures has been your mission and mantra since you founded the program. Can you give us some examples of the most promising research?
I am so excited about our research. We have about 20 different disease-focused teams. That includes physicians, nurses, health care staff, researchers and faculty members, all working to go from the laboratory bench to patient's bedside with therapies.
Perhaps the most promising and exciting research right now comes from combining blood-forming
stem cells with gene therapy. We're working in about eight areas right now, and the first cure, something that we definitely can call a stem cell "cure," is coming from this combined approach.
Soon, doctors will be able to prescribe this type of stem cell therapy. Patients will use their own bone marrow or umbilical cord stem cells. Teams such as ours, working in good manufacturing practice facilities, will make vectors, essentially "biological delivery vehicles," carrying a good copy of the broken gene. They will be reinserted into a patient's cells and then infused back into the patient, much like a bone marrow transplant.
"Perhaps the most promising and exciting research right now comes from combining blood-forming stem cells with gene therapy."
Along with treating the famous bubble baby disease, where I had started my career, this approach looks very promising for sickle cell anemia. We're hoping to use it to treat several different inherited metabolic diseases. These are conditions characterized by an abnormal build-up of toxic materials in the body's cells. They interfere with organ and brain function. It's caused by just a single enzyme. Using the combined stem cell gene therapy, we can effectively put a good copy of the gene for that enzyme back into a patient's bone marrow stem cells. Then we do a bone marrow transplantation and bring back a person's normal functioning cells.
The beauty of this therapy is that it can work for the lifetime of a patient. All of the blood cells circulating in a person's system would be repaired. It's the number one stem cell cure happening right now. Plus, it's a therapy that won't be rejected. These are a patient's own stem cells. It is just one type of stem cell, and the first that's being commercialized to change cells throughout the body.
Q: Let's step back for a moment. In 2004, voters approved Proposition 71. It has funded a majority of the stem cell research here at UC Davis and throughout California. What's been the impact of that ballot measure and how is it benefiting patients?
We have learned so much about different types of stem cells, and which stem cell will be most appropriate to treat each type of disease. That's huge. We had to first do that before being able to start actual stem cell therapies. CIRM [California Institute for Regenerative Medicine] has funded Alpha Stem Cell Clinics. We have one of them here at UC Davis and there are only five in the entire state. These are clinics where the patients can go for high-quality clinical stem cell trials approved by the FDA [U.S. Food and Drug Administration]. They don't need to go to "unapproved clinics" and spend a lot of money. And they actually shouldn't.
"By the end of this year, we'll have 50 clinical trials."
By the end of this year, we'll have 50 clinical trials [here at UC Davis Health]. There are that many in the works.
Our Alpha Clinic is right next to the hospital. It's where we'll be delivering a lot of the immunotherapies, gene therapies and other treatments. In fact, I might even get to personally deliver stem cells to the operating room for a patient. It will be for a clinical trial involving people who have broken their hip. It's exciting because it feels full circle, from working in the laboratory to bringing stem cells right to the patient's bedside.
We have ongoing clinical trials for critical limb ischemia, leukemia and, as I mentioned, sickle cell disease. Our disease teams are conducting stem cell clinical trials targeting sarcoma, cellular carcinoma, and treatments for dysphasia [a swallowing disorder], retinopathy [eye condition], Duchenne muscular dystrophy and HIV. It's all in the works here at UC Davis Health.
There's also great potential for therapies to help with renal disease and kidney transplants. The latter is really exciting because it's like a mini bone marrow transplant. A kidney recipient would also get some blood-forming stem cells from the kidney donor so that they can better accept the organ and not reject it. It's a type of stem cell therapy that could help address the burden of being on a lifelong regime of immunosuppressant drugs after transplantation.
Q: You and your colleagues get calls from family members and patients all the time. They frequently ask about stem cell "miracle" cures. What should people know about unproven treatments and unregulated stem cell clinics?
That's a great question.The number one rule is that if you're asked to pay money for a stem cell treatment, don't do it. It's a big red flag.
When it comes to advertised therapies: "The number one rule is that if you're asked to pay money for a stem cell treatment, don't do it. It's a big red flag."
Unfortunately, there are unscrupulous people out there in "unapproved clinics" who prey on desperate people. What they are delivering are probably not even stem cells. They might inject you with your own fat cells, which contain very few stem cells. Or they might use treatments that are not matched to the patient and will be immediately rejected. That's dangerous. The FDA is shutting these unregulated clinics down one at a time. But it's like "whack-a-mole": shut one down and another one pops right up.
On the other hand, the Alpha Clinic is part of our mission is to help the public get to the right therapy, treatment or clinical trial. The big difference between those who make patients pay huge sums of money for unregulated and unproven treatments and UC Davis is that we're actually using stem cells. We produce them in rigorously regulated cleanroom facilities. They are certified to contain at least 99% stem cells.
Patients and family members can always call us here. We can refer them to a genuine and approved clinical trial. If you don't get stem cells at the beginning [of the clinical trial] because you're part of the placebo group, you can get them later. So it's not risky. The placebo is just saline. I know people are very, very desperate. But there are no miracle cures…yet. Clinical trials, approved by the FDA, are the only way we're going to develop effective treatments and cures.
Q: Scientific breakthroughs take a lot of patience and time. How do you and your colleagues measure progress and stay motivated?
Motivation? "It's all for the patients."
It's all for the patients. There are not good therapies yet for many disorders. But we're developing them. Every day brings a triumph. Measuring progress means treating a patient in a clinical trial, or developing something in the laboratory, or getting FDA approval. The big one will be getting biological license approval from the FDA, which means a doctor can prescribe a stem cell or gene therapy treatment. Then it can be covered by a patient's health insurance.
I'm a cancer survivor myself, and I'm also a heart patient. Our amazing team here at UC Davis has kept me alive and in great health. So I understand it from both sides. I understand the desperation of "Where do I go?" and "What do I do right now?" questions. I also understand the science side of things. Progress can feel very, very slow. But everything we do here at the Institute for Regenerative Cures is done with patients in mind, and safety.
We know that each day is so important when you're watching a loved one suffer. We attend patient events and are part of things like Facebook groups, where people really pour their hearts out. We say to ourselves, "Okay, we must work harder and faster." That's our motivation: It's all the patients and families that we're going to help who keep us working hard.
Breaking bad news to stem cell researchers
July 1, 2019 / Kevin McCormack	/ 6 Comments
It's never easy to tell someone that they are too late, that they missed the deadline. It's particularly hard when you know that the person you are telling that to has spent years working on a project and now needs money to take it to the next level. But in science, as in life, it's always better to tell people what they need to know rather than what they would like to hear.
And so, we have posted a notice on our website for researchers thinking about applying for funding that, except in a very few cases, they are too late, that there is no money available for new projects, whether it's Discovery, Translational or Clinical.
Here's that notice:
CIRM anticipates that the budget allocation of funds for new awards under the CIRM clinical program (CLIN1, CLIN2 and CLIN3) may be depleted within the next two to three months. CIRM will accept applications for the monthly deadline on June 28, 2019 but will suspend application submissions after that date until further notice. All applicants should note that the review of submitted applications may be halted at any point in the process if funds are depleted prior to completion of the 3-month review cycle. CIRM will notify applicants of such an occurrence. Therefore, submission and acceptance of an application to CIRM does not guarantee the availability of funds or completion of a review cycle.
The submission of applications for the CIRM/NHLBI Cure Sickle Cell Initiative (CLIN1 SCD, CLIN2 SCD) are unaffected and application submissions for this program will remain open.
We do, of course, have enough money set aside to continue funding all the projects our Board has already approved, but we don't have money for new projects (except for some sickle cell disease projects).
In truth our funding has lasted a lot longer than anyone anticipated. When Proposition 71 was approved the plan was to give CIRM $300 million a year for ten years. That was back in 2004. So what happened?
Well, in the early years stem cell science was still very much in its infancy with most of the work being done at a basic or Discovery level. Those typically don't require very large sums so we were able to fund many projects without hitting our $300m target. As the field progressed, however, more and more projects were at the clinical trial stage and those need multiple millions of dollars to be completed. So, the money went out faster.
To date we have funded 55 clinical trials and our early support has helped more than a dozen other projects get into clinical trials. This includes everything from cancer and stroke, to vision loss and diabetes. It's a good start, but we feel there is so much more to do.
Followers of news about CIRM know there is talk about a possible ballot initiative next year that would provide another $5.5 billion in funding for us to help complete the mission we have started.
Over the years we have built a pipeline of promising projects and without continued support many of those projects face a difficult future. Funding at the federal level is under threat and without CIRM there will be a limited number of funding alternatives for them to turn to.
Telling researchers we don't have any money to support their work is hard. Telling patients we don't have any money to support work that could lead to new treatments for them, that's hardest of all.
CIRM & NHLBI Create Landmark Agreement on Curing Sickle Cell Disease
April 30, 2019 / Yimy Villa	/ Leave a comment
CIRM Board approves first program eligible for co-funding under the agreement
Adrienne Shapiro, co-founder of Axis Advocacy, with her daughter Marissa Cors, who has Sickle Cell Disease.
Sickle Cell disease (SCD) is a painful, life-threatening blood disorder that affects around 100,000 people, mostly African Americans, in the US. Even with optimal medical care, SCD shortens expected lifespan by decades. It is caused by a single genetic mutation that results in the production of "sickle" shaped red blood cells. Under a variety of environmental conditions, stress or viral illness, these abnormal red blood cells cause severe anemia and blockage of blood vessels leading to painful crisis episodes, recurrent hospitalization, multi-organ damage and mini-strokes.
On April 29th the governing Board of the California Institute for Regenerative Medicine (CIRM) approved $4.49 million to Dr. Mark Walters at UCSF Benioff Children's Hospital in Oakland to pursue a gene therapy cure for this devastating disease. The gene therapy approach uses CRISPR-Cas9 technology to correct the genetic mutation that leads to sickle cell disease. This program will be eligible for co-funding under the landmark agreement between CIRM and the National Heart, Lung and Blood Institute (NHLBI) of the NIH.
This CIRM-NHLBI agreement was finalized this month to co-fund cell and gene therapy programs under the NIH "Cure Sickle Cell" initiative. The goal is to markedly accelerate the development of cell and gene therapies for SCD. It will deploy CIRM's resources and expertise that has led to a portfolio of over 50 clinical trials in stem cell and regenerative medicine.
"CIRM currently has 23 clinical stage programs in cell and gene therapy. Given the advancements in these approaches for a variety of unmet medical needs, we are excited about the prospect of leveraging this to NIH-NHLBI's Cure Sickle Cell Initiative," says Maria T. Millan, M.D., the President and CEO of CIRM. "We are pleased the NHLBI sees value in CIRM's acceleration and funding program and look forward to the partnership to accelerate cures for sickle cell disease."
"There is a real need for a new approach to treating SCD and making life easier for people with SCD and their families," says Adrienne Shapiro, the mother of a daughter with SCD and the co-founder of Axis Advocacy, a sickle cell advocacy and education organization. "Finding a cure for Sickle Cell would mean that people like my daughter would no longer have to live their life in short spurts, constantly having their hopes and dreams derailed by ER visits and hospital stays. It would mean they get a chance to live a long life, a healthy life, a normal life."
CIRM is currently funding two other clinical trials for SCD using different approaches. One of these trials is being conducted at City of Hope and the other trial is being conducted at UCLA.
Mending Stem Cells: The Past, Present & Future of Regenerative Medicine
April 9, 2019 / Kevin McCormack	/ Leave a comment
UCSF's Mission Bay Campus
For years we have talked about the "promise" and the "potential" of stem cells to cure patients. But more and more we are seeing firsthand how stem cells can change a patient's life, even saving it in some cases. That's the theme of the 4th Annual CIRM Alpha Stem Cell Clinics Network Symposium.
It's not your usual symposium because this brings together all the key players in the field – the scientists who do the research, the nurses and doctors who deliver the therapies, and the patients who get or need those therapies. And, of course, we'll be there; because without CIRM's funding to support that research and therapies none of this happens.
We are going to look at some of the exciting progress being made, and what is on the horizon. But along the way we'll also tackle many of the questions that people pose to us every day. Questions such as:
How can you distinguish between a good clinical trial offering legitimate treatments vs a stem cell clinic offering sham treatments?
What about the Right to Try, can't I just demand I get access to stem cell therapies?
How do I sign up for a clinical trial, and how much will it cost me?
What is the experience of patients that have participated in a stem cell clinical trial?
World class researchers will also talk about the real possibility of curing diseases like sickle cell disease on a national scale, which affect around 100,000 Americans, mostly African Americans and Hispanics. They'll discuss the use of gene editing to battle hereditary diseases like Huntington's. And they'll highlight how they can engineer a patient's own immune system cells to battle deadly cancers.
So, join us for what promises to be a fascinating day. It's the cutting edge of science. And it's all FREE.
Here's where you can go to find out more information and to sign up for the event.
CRISPR-Cas9 101: an overview and the role it plays in developing therapies
April 5, 2019 / Yimy Villa	/ 3 Comments
Illustration courtesy of TED website
There has been a lot of conversation surrounding CRISPR-Cas9 in these recent months as well as many sensational news stories. Some of these stories highlight the promise this technology holds, while others emphasize a word of caution. But what exactly does this technology do and how does it work? Here is a breakdown that will help you better understand.
To start off, CRISPR is a naturally occurring process found in bacteria used as an immune system to defend against viruses. CRISPR simply put, are strands of DNA segments that contain repeating patterns. There are "scissor like" CRISPR proteins that have the ability to cut DNA segments. When a copy of a virus enters the bacteria, these "scissor like" proteins cut a segment of DNA from the virus and insert it into CRISPR. A copy of the viral DNA is made and another "attack" protein known as Cas9 attaches to it. By binding to the viral copy, Cas9 is able to sense that virus. When the same virus tries to enter the bacteria, Cas9 is able to seek and destroy it.
You can view a more detailed video explaining this concept below.
Many scientists analyzed this process in detail and it was eventually discovered that this CRISPR-Cas9 complex could be used to removed unwanted genes and insert a corrected copy, revolutionizing the way that we view the approach towards treating a wide variety of genetic diseases.
In fact, researchers at the Dana-Farber/Boston Children's Cancer and Blood Disorders Center and the University of Massachusetts Medical School have developed a strategy using this complex to treat two inherited, lethal blood disorders, sickle cell disease (SCD) and beta thalassemia. Both of these diseases involve a mutation that effects production of red blood cells, which are produced by blood stem cells. In beta-thalassemia, the mutation prevent red blood cells from being able to carry enough oxygen, leading to anemia. In SCD, the mutations cause red blood cells to take on a "sickle" shape which can block blood vessels.
By using CRISPR-Cas9 to insert a corrected copy of the gene into a patient's own blood stem cells, this team demonstrated that functional red blood cells can then be produced. These results pay the way for other blood disorders as well.
In a press release , Dr. Daniel Bauer, an attending physician with Dana-Farber and a senior author on both of these studies stated that,
"Combining gene editing with an autologous stem-cell transplant could be a therapy for sickle-cell disease, beta-thalassemia and other blood disorders."
In a separate study, scientists at University of Massachusetts Medical School have developed a strategy that could be used to treat genetic disorders associated with unintentional repeats or copies of small DNA segments. These problematic small segments of DNA are called microduplications and cause as many as 143 different diseases, including limb-girdle muscular dystrophy, Hermansky-Pudlak syndrome, and Tay-Sachs.
Because these are issues caused by repeats or copies of small DNA segments, the CRISPR-Cas9 complex can be used to remove microduplications without having to insert any additional genetic material.
Dr. Scot A. Wolfe, a co-investigator of this study, stated that,
"It's like hitting the reset button. We don't have to add any corrective genetic material, instead the cell stitches the DNA back together minus the duplication. It's a shortcut for gene correction with potential therapeutic appeal."
Although there has been a lot progress made with this technology, there are still concerns that need to be addressed. An article in Science mentions how two studies have shown that CRISPR can still make unintended changes to DNA, which can be potentially dangerous. In the article, Dr. Jin-Soo Kim, a CRISPR researcher at Seoul National University is quoted as saying,
"It is now important to determine which component is responsible for the collateral mutations and how to reduce or avoid them."
Overall, CRISPR-Cas9 has revolutionized the approach of precision medicine. A wide variety of diseases are caused by small, unexpected segments of DNA. By applying this approach found in bacteria to humans, we have uncovered a way to correct these segments at the microscopic level. However, there is still much that needs to be learned and perfected before it can be utilized in patients.
Facebook Live – Ask the Stem Cell Team about Patient Advocacy
March 12, 2019 / Kevin McCormack	/ 3 Comments
How often do you get to ask an expert a question about something that matters deeply to you and get an answer right away? Not very often I'm guessing. That's why CIRM's Facebook Live "Ask the Stem Cell Team About Patient Advocacy" gives you a chance to do just that this Thursday, March 14th from noon till 1pm PST.
We have three amazing individuals who will share their experiences, their expertise and advice as Patient Advocates, and answer your questions about how to be an effective advocate for your cause.
The three are:
Gigi McMillan became a Patient Advocate when her 5-year-old son was diagnosed with a brain tumor. That led her to helping develop support systems for families going through the same ordeal, to help researchers develop appropriate consent processes and to campaign for the rights of children and their families in research.
Adrienne Shapiro comes from a family with a long history of Sickle Cell Disease (SCD) and has fought to help people with SCD have access to compassionate care. She is the co-founder of Axis Advocacy, an organization dedicated to raising awareness about SCD and support for those with it. In addition she is now on the FDA's Patient Engagement Collaborative, a new group helping the FDA ensure the voice of the patient is heard at the highest levels.
David Higgins is a CIRM Board member and a Patient Advocate for Parkinson's Disease. David has a family history of the disease and in 2011 was diagnosed with Parkinson's. As a scientist and advocate he has championed research into the disease and worked to raise greater awareness about the needs of people with Parkinson's.
Also, make sure to "like" our FaceBook page before the event to receive a notification when we've gone live for this and future events. If you miss the broadcast, not to worry. We'll be posting it on our Facebook video page, our website, and YouTube channel shortly afterwards.
We want to answer your most pressing questions, so please email them directly to us beforehand at info@cirm.ca.gov.
And, of course, feel free to share this information with anyone you think might be interested.


This lovely plant puts out fiery HOT peppers and does double duty as a gorgeous ornamental plant filled with dozens and dozens of colorful peppers. Perfect when cooking spicy cuisine, chili, stews, or of course, a must-have for salsa. Also good dried in a ristra.


Hodgson Russ assisted an officer and shareholder of a corporation alleged to have received a constructive dividend from the corporation, resulting in alleged New York State and collateral federal personal income tax liabilities. Our attorneys successfully sought a courtesy conference with the New York State Department of Taxation and Finance, resulting in the cancellation of the assessment and a refund of the erroneously seized funds. Subsequently, we sought audit reconsideration with the Internal Revenue Service challenging the collateral assessment of federal income tax liability. This, too, resulted in the cancellation of the assessment and a refund of the erroneously withheld refunds.


It has to be underlined that there is no sense in picking between Physical Repositories and Digital Data Rooms inasmuch as all is clear. On the other hand, not all the enterprises agree with us and still choose to use the traditional data rooms for storing their closet documentation. Therefore, what is wrong with ordinary depositories and why do we offer you to dig for the modern data rooms? We'll see together.
Traditional data rooms are sensitive to data leakage. But the Electronic Data Rooms use the pertinent safety features to provide your archival depositories with the advanced protection. The most forward-minded virtual data room providers hack their own Secure Online Data Rooms to check the safety. We advise you to pick only the certified Virtual Rooms . By such manners, you will not become a victim of the information disclosure and will enjoy the safe Electronic Repositories.
Having selected Electronic Data Rooms , you will get such positive sides as the overnight technical support, the electronic translator, many languages interface, the Q&A etc. In cases when you plan to be occupied with the M&A dealing, you will see that it will become more efficient. All your depositors will enjoy such possibilities which save plenty of time and money.
It is no secret that both land-based repositories and modern deal rooms have their good points and minuses. But as a matter of fact, the only good point of Physical Repositories is keeping the archives. But still, the Virtual Repositories can offer you much more. In the very beginning, it is a secure keeping of your information. Then, there is the great selection of various Due Diligence rooms and you are able to choose the Virtual Data Rooms in conformity with your scopes of activity, financial position, taste, needs etc. Everybody knows that there are inexpensive and sumptuous VDR services, but normally, both of them suggest you gratuitous trials which let you test large numbers of Up-to-date Deal Rooms and decide on the excellent one. There are Electronic Repositories without free trials and it is a good idea not to select them. On the contrary, on conditions that the opinions of people are positive, you could try.
With the Digital Data Rooms, your business partners from diverse countries will not go anywhere to skip through your records. What they need is the Worldwide Web, personal computers or mobile devices and an access to your Up-to-date Deal Rooms.
Do you have a desire to work with papers in cases when there are differing document formats in these latter days? Every corporation is free to pick the best file formats and deal with them. It is self-evident that the only format you can store in the land-based venues is papers. On the other way around, in relation to the Electronic Repositories , you have the right to keep large numbers of file formats and convert them.
Bandying about conventional data rooms, we will say that your private files will not be protected from the natural disasters. Consequently, you can lose your information. As concerns Electronic Data Rooms, they also store the information on the physical file servers. Nevertheless, basically, the majority of Virtual Platforms virtual data room keep the archives on many file servers throughout the entire Planet. Hence, you will not become a sacrifice of the security leak.
Therefore, we can claim that your choice is obvious but you have to come to the decision. By the same token, do not be afraid of spending great sums of money on the Virtual Repositories, we just want you to do not forget about the great selection of affordable virtual data room providers which suggest you all the same good points.
This entry was posted in Data Room by admin. Bookmark the permalink.


Each morning, I'm awoken to the sound of my host mother's voice just outside my door, "venga al desayuno, Andrecito." (Come to breakfast, Andrecito.) (Well, initially I'm awoken to the sound of roosters crowing outside my window at 4am, but that's beside the point.) Before me, there is usually a breakfast quite uncharacteristic of what one would consider breakfast: no eggs, no bacon, and most unfortunately, no pancackes. To give you some perspective one meal actually consisted of solely beans and choclo (similar to corn).
After breakfast, its time to begin my daily trek up the mountain and into the town of Apuela. This hike usually takes me anywhere from 30 to 45 minutes depending on the weather (or how tired I am). For me, this is a time for meditation and mental contemplation, though there is no set thing I contemplate on. I could be thinking about anything from dreams I've had to how I'm feeling emotionally at the moment, or sometimes I just take in the breathtaking landscape. Though, often times, my mind simply wanders, a myriad of thoughts and ideas. I often feel as if I'm the last man on Earth, adopting the nomadic lifestyle of my primitive ancestors, which is a pretty easy idea to entertain, considering its extremely rare to encounter anyone on the road, except on Sundays.
Ultimately, my feelings on my silent hikes remain mixed, as you may well imagine: a half an hour walk daily has the potential to grow quite wearisome. On the positive side of things, I feel these hikes also maintain a therapeutic aspect. As we learned on our silent hike during Fall Training, they allow me to take a step back and sort out my thoughts and feelings in times of hardship. In addition to therapeutic benefits, naturally, a hike up a mountain everyday has its physical benefits too. So with luck, by the end of 6 months I'll be "más fuerte!" (stronger).


I am really taking a liking to Google Chrome. The more I use it the more fun I have and the faster I get my daily tasks done. I am thinking about doing a whole series on Google Chrome because they have so many cool add-ons like "Print Friendly." I have had a few complaints from converts to Chrome, saying that in Internet Explorer they could highlight a paragraph and then right click on it and print just the selected text. This is a problem for those who believe in saving paper and ink. I don't want the whole page, I just want part of it. Sooooo, what is the solution? Print Friendly.
Print Friendly immediately deletes all ads that are found on the page so you don't end up printing them.
It allows you to delete any picture, paragraph, or title from the page.
You literally get to print the parts that you want.
What are some drawback to using Print Friendly?
To be honest, none that I have seen except an annoying ad that you have to close when you are done printing.
6. In the search box type in "Print Friendly," and then hit enter.
7. Find the "Print Friendly" extension and then click the "Add to Chrome" button.
8. A box will pop up, click the "Install" button.
9. At the top of Chrome you will now see a "print" icon. When you find a page that you want to print portions of, click the "Print" icon.
10. A box with the webpage and the pictures will then pop up. Notice that all the ads have already disappeared.
11. Hover your mouse over any portion of the page that you do not want to print and then click on it. It will instantly remove that section and shift everything up.
12. At the top of the box you have a few options. You can change the font size, choose to delete all pictures at once. You can also undo any mistakes that you may have made when deleting.
13. Once you have made your document adjustments you can print, email, or change the document to a PDF.
Well there you have it. Another fine tool created to help educators get their job done nicer, neater, and quicker.
I do not want the whole page, I just need to be part of it. So, what are solutions? Friendly printing.


With the Final Four coming to Minneapolis this weekend, the focus will be on basketball — but music fans will have something to celebrate, too.
Big-ticket acts like Katy Perry, the Jonas Brothers and the Chainsmokers will all perform free shows at the Minneapolis Armory. Tickets for those concerts have been snapped up, but there will be free unticketed outdoor performances and events all weekend on the Nicollet Mall.


Transcatheter aortic valve implantation (TAVI) has become a valuable alternative to aortic valve replacement (AVR) for surgical high-risk patients with severe aortic stenosis. Due to technical improvements and increased operator experience the valve implantation success has become very high. Nevertheless, the post procedural recovery in these elderly patients is often prolonged. We aimed to evaluate clinical and demographic predictors of a prolonged hospital stay in patients undergoing TAVI.
We included 187 consecutive patients with severe aortic stenosis who underwent TAVI. The valve was implanted by transfemoral technic in 180 (96.3%), transapical in 2 (1.1%) and via the subclavian artery in 5 (2.7%) patients. We implanted 160 (85.6%) CoreValve and 27 (14.4%) Edwards Sapien prostheses. Logistic regression was used to determine the factors affecting length of stay longer than median.
Median of length of stay was 7 days. Pulmonary hypertension above 60mmHg, prior ischemic stroke, EuroSCORE II above median (5.3%) and previous cardiac surgery did not have significant influence on the length of hospital stay (LOS). The following parameters could be identified as predictors of a hospital stay > 7 days (table 1).
Age above 85, STS-Score above median (5.6%), female gender, state of chronic renal failure ≥ 3, logistic EuroSCORE above median (14.7%) are associated with an increased risk of a longer hospital stay after TAVI. Independent predicting risk factors are only the STS Score above median (5.6%) and the age above 85.


The Plainview Primary Comprehensive Counseling Program was redeveloped and updated spring 2016 and was approved by the Plainview School Board at the 2016 March meeting. This plan will be updated each year as needed. This plan can be accessed below and is included in the Plainview District Comprehensive Counseling Program.
The Plainview District Comprehensive Counseling Program was redeveloped and updated spring 2016 and was approved by the School Board at the 2016 March meeting. This plan will be updated each year as needed. This document is filed in the Administrative Building and can be accessed below.


The European Disability Strategy 2010-2020 adopted by the European Commission in November 2010, represents a fundamental policy instrument for persons with disabilities and their organisations to be used in order to make a barrier-free Europe.
The Strategy identifies eight main areas for action: Accessibility, Participation, Equality, Employment, Education and Training, Social Protection, Health, and External Action.
On 23 December 2015, the European Commission launched a public consultation on the review of the European Disability Strategy 2010-2020. EDF submitted its position on the review of the Strategy.
the Strategy should be part of the social pillar proposed by the European Commission to address social exclusion, poverty, unemployment and access to education.


text:
Q: Is the meaning of the acronym "FAQ" generally understood? When people see the acronym FAQ, I wonder if they really know what it stands for or whether they just understand the concept.
Is this true for most native English speakers?

A: It's hard to answer this question precisely, but in my experience (native English speaker from the USA) it is generally understood what FAQ stands for ("frequently asked questions"), at least, so long as the person is familiar with what an FAQ is in concept.  I have heard of people knowing the abbreviation but not knowing what it stands for, but this seems to be enough of an exception that it's considered noteworthy.


Items where Journal is "10th Salford Postgraduate Annual Research Conference (SPARC'08)"
Mihindu, SA, Khosrowshahi, F and Egbu, CO 2008, Intelligent building infrastructures that provide enhanced collaborative environments for its occupants - future scenarios , in: 10th Salford Postgraduate Annual Research Conference (SPARC'08), 8th - 9th May 2008, The University of Salford, UK. Item not available from this repository.
This list was generated on Fri Apr 19 01:06:32 2019 UTC.


Automated lighting manufacturer High End Systems introduces SolaFrame 1000, calling it "the new go-to workhorse automated framing fixture for lighting designers." SolaFrame 1000 offers 20,000 field lumen output, full framing shutters, rotating and fixed gobo wheels, a new CMY and CTO color mixing system, 12°-40° zoom, replaceable color wheels and continuously variable animation effects.
An ETC Company, High End Systems is a leading manufacturer of automated lighting and control for the entertainment industry. For more information on High End Systems, visit www.highend.com. For more information on SolaFrame 1000, visit www.highend.com/products/lighting/solaframe.


text:
Q: How to Add a text in Email Body with a attachment Here I have made this code to send mails with an attachment. I need to write "Dear All, Please find attached mail" on email body and add attachement.
# Define the HTML document
mail_content = '''Dear All,
Please find below attachement
'''

# Define a function to attach files as MIMEApplication to the email
##############################################################
def attach_file_to_email(email_message, filename):
    # Open the attachment file for reading in binary mode, and make it a MIMEApplication class
    with open(filename, "rb") as f:
        file_attachment = MIMEApplication(f.read())
    # Add header/name to the attachments
    file_attachment.add_header(
        "Content-Disposition",
        f"attachment; filename= {filename}",
    )
    # Attach the file to the message
    email_message.attach(file_attachment)
##############################################################

# Set up the email addresses and password. Please replace below with your email address and password
email_from = 'Network.Alert@me.lk'
email_to = 'jon@me.lk'

# Generate today's date to be included in the email Subject
date_str = pd.Timestamp.today().strftime('%Y-%m-%d')

# Create a MIMEMultipart class, and set up the From, To, Subject fields
email_message = MIMEMultipart()

email_message['From'] = email_from
email_message['To'] = email_to
email_message['Cc'] = Cc

email_message['Subject'] = f'Report email - {date_str}'

# Attach the html doc defined earlier, as a MIMEText html content type to the MIME message
email_message.attach(MIMEText(html, "html"))

# Attach more (documents)
##############################################################
attach_file_to_email(email_message, '/data/Stat20220419.csv')

##############################################################
# Convert it as a string
email_string = email_message.as_string()

try:
   smtpObj = smtplib.SMTP('mail.protection.outlook.com',25)
   smtpObj.sendmail(email_from, ['new@me.lk], email_string)
   print ("Successfully sent email")
except smtplib.SMTPException:
    pass
except smtplib.socket.error:
    pass

Can someone show me how to add to the mail_content to mail body. I have used email_message.attach but it is attaching anothe text file with the text. But I need to show just text in the body.Can someone help?


text:
Cities and Towns in Door County, Wisconsin
Founded in 1851, Door County is one of 72 counties in the state of Wisconsin. Historically, Door County was formed from Brown County. The city of Sturgeon Bay is the county seat. With FIPS code of 29, Door County has a population of 30,369 and area of 481.98 square miles (1,248 km2).
List of all cities in Door County, WI alphabetically
Baileys Harbor, WI
Brussels, WI
Egg Harbor, WI
Ellison Bay, WI
Ephraim, WI
Fish Creek, WI
Forestville, WI
Sister Bay, WI
Sturgeon Bay, WI
Washington Island, WI
Cities and Towns in Forest County, Wisconsin
Cities and Towns in Pepin County, Wisconsin
Cities and Towns in Pierce County, Wisconsin
Cities and Towns in Polk County, Wisconsin
Cities and Towns in Portage County, Wisconsin
Cities and Towns in Price County, Wisconsin
Cities and Towns in Racine County, Wisconsin
Cities and Towns in Richland County, Wisconsin
Cities and Towns in Ozaukee County, Wisconsin
Cities and Towns in Outagamie County, Wisconsin
Cities and Towns in Oneida County, Wisconsin
Cities and Towns in Oconto County, Wisconsin
Cities and Towns in Monroe County, Wisconsin


Hello, my name is Ralph Moore III and I have been making your backyard dreams a reality for over 20 years. As Construction Manager, I work hard laying out each pool to ensure your backyard is made into an oasis of fun and memories.
I look forward to speaking with you and I can be reached by phone at 518-783-9242 ext 18.